Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07517653
PHASE2

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Sponsor: Shanghai Zhongshan Hospital

View on ClinicalTrials.gov

Summary

This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma

Official title: A Multicenter, Phase II Clinical Trial of Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma (The ASPRIE-MM Study)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2026-04-01

Completion Date

2028-12-30

Last Updated

2026-04-08

Healthy Volunteers

No

Conditions

Interventions

DRUG

SHR-1701

Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China

DRUG

Famitinib

Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China